clinical trial · NCT05511519
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
Psoriatic ArthritisATI-450Placebo Oral Tablet
brief summary
This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
started
Jul 12, 2022
primary completion
Dec 6, 2023
completion
Jan 3, 2024
last updated
Nov 27, 2024
detailed description
This is a Phase 2a, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
official title
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients With Moderate-to-Severe Active Psoriatic Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol